Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Golimumab on Endothelial Progenitor Cells and Vascular Stiffness in Ankylosing Spondylitis
NCT01212653Phase 4Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Oct 2010
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of golimumab in ankylosing spondylitis (AS) (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Effect of Golimumab treatment on the progression of subclinical atherosclerosis at 12 months. Started Oct 2010; status: completed.
02
Drugs
golimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT01212653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01212653.